Nurix Therapeutics Inc Total Liabilities
Nurix Therapeutics Inc total liabilities. Based on the latest financial reports, Nurix Therapeutics Inc (NRIX) has total liabilities worth $150.22 Million USD as of August 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check NRIX asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Nurix Therapeutics Inc (2018–2024)
Total liabilities of Nurix Therapeutics Inc from 2018 to 2024. This chart illustrates how Nurix Therapeutics Inc's total liabilities have evolved over time, based on quarterly financial data. Explore Nurix Therapeutics Inc long-term investment allocation to see how much of total assets are deployed in long-term investments.
Nurix Therapeutics Inc Competitors by Total Liabilities
The table below lists competitors of Nurix Therapeutics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Guangxi Guitang Group Co Ltd
SHE:000833
|
China | CN¥3.45 Billion |
|
Anhui Heli Co Ltd
SHG:600761
|
China | CN¥9.14 Billion |
|
Shenyang Jinshan Energy Co Ltd
SHG:600396
|
China | CN¥9.63 Billion |
|
Mirgor S.A.
BA:MIRG
|
Argentina | AR$1.47 Trillion |
|
China Wafer Level Csp Co Ltd
SHG:603005
|
China | CN¥529.55 Million |
|
Arcplus Group PLC
SHG:600629
|
China | CN¥9.04 Billion |
|
La Comer S.A.B. de C.V
MX:LACOMERUBC
|
Mexico | MX$8.02 Billion |
|
Hebei Huatong Wires and Cables Group Co. Ltd.
SHG:605196
|
China | CN¥8.08 Billion |
Liability Composition Analysis (2018–2024)
This chart breaks down Nurix Therapeutics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see NRIX asset base.
Liquidity & Leverage Metrics
Nurix Therapeutics Inc Total Liabilities Ratios Explained
Nurix Therapeutics Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 5.35 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.40 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.29 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Nurix Therapeutics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Nurix Therapeutics Inc (2018–2024)
The table below shows the annual total liabilities of Nurix Therapeutics Inc from 2018 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-11-30 | $142.35 Million | -8.22% |
| 2023-11-30 | $155.10 Million | +37.18% |
| 2022-11-30 | $113.06 Million | -15.92% |
| 2021-11-30 | $134.47 Million | +26.77% |
| 2020-11-30 | $106.07 Million | +98.02% |
| 2019-11-30 | $53.57 Million | +57.32% |
| 2018-11-30 | $34.05 Million | -- |
About Nurix Therapeutics Inc
Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and antibody therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-5948, an orally bioavailable BTK degrader, that is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory B-ce… Read more